Optimal plasticity for memory maintenance during ongoing synaptic change.

Synaptic connections in many brain circuits fluctuate, exhibiting substantial turnover and remodelling over hours to days. Surprisingly, experiments show that most of this flux in connectivity persists in the absence of learning or known plasticity signals. How can neural circuits retain learned information despite a large proportion of ongoing and potentially disruptive synaptic changes? We address this question from first principles by analysing how much compensatory plasticity would be required to optimally counteract ongoing fluctuations, regardless of whether fluctuations are random or systematic. Remarkably, we find that the answer is largely independent of plasticity mechanisms and circuit architectures: compensatory plasticity should be at most equal in magnitude to fluctuations, and often less, in direct agreement with previously unexplained experimental observations. Moreover, our analysis shows that a high proportion of learning-independent synaptic change is consistent with plasticity mechanisms that accurately compute error gradients

Shot-noise-limited spin measurements in a pulsed molecular beam

Heavy diatomic molecules have been identified as good candidates for use in electron electric dipole moment (eEDM) searches. Suitable molecular species can be produced in pulsed beams, but with a total flux and/or temporal evolution that varies significantly from pulse to pulse. These variations can degrade the experimental sensitivity to changes in spin precession phase of an electri- cally polarized state, which is the observable of interest for an eEDM measurement. We present two methods for measurement of the phase that provide immunity to beam temporal variations, and make it possible to reach shot-noise-limited sensitivity. Each method employs rapid projection of the spin state onto both components of an orthonormal basis. We demonstrate both methods using the eEDM-sensitive H state of thorium monoxide (ThO), and use one of them to measure the magnetic moment of this state with increased accuracy relative to previous determinations.Comment: 12 pages, 6 figure

Lepton Polarization Asymmetry in B l l(bar) decays in R-parity violating Minimal Supersymmetric Standard Model

We study the implication of R-parity violating Rp Minimal Supersymmetric Standard Model (MSSM) model in lepton polarization asymmetry ALP in B l l(bar) decays . The analysis show that the ALP is significant in a certain phenomenological parametric region of Yukawa couplings. We have also placed indirect bounds on Lambda' lambda couplings as obtained from B t t(bar).Comment: 6 pages, 4 figures Changes of notation in Eq(8-11,17-19),Eq.20 adde

Vibrational Sum Frequency Spectroscopic Investigation of the Azimuthal Anisotropy and Rotational Dynamics of Methyl-Terminated Silicon(111) Surfaces

Polarization-selected vibrational sum frequency generation spectroscopy (SFG) has been used to investigate the molecular orientation of methyl groups on CH_(3)-terminated Si(111) surfaces. The symmetric and asymmetric C–H stretch modes of the surface-bound methyl group were observed by SFG. Both methyl stretches showed a pronounced azimuthal anisotropy of the 3-fold symmetry in registry with the signal from the Si(111) substrate, indicating that the propeller-like rotation of the methyl groups was hindered at room temperature. The difference in the SFG line widths for the CH_3 asymmetric stretch that was observed for different polarization combinations (SPS and PPP for SFG, visible, and IR) indicated that the rotation proceeded on a 1–2 ps time scale, as compared to the 100 fs rotational dephasing of a free methyl rotor at room temperature

Resistance to paclitaxel in a cisplatin-resistant ovarian cancer cell line is mediated by P-glycoprotein

The IGROVCDDP cisplatin-resistant ovarian cancer cell line is also resistant to paclitaxel and models the resistance phenotype of relapsed ovarian cancer patients after first-line platinum/taxane chemotherapy. A TaqMan low-density array (TLDA) was used to characterise the expression of 380 genes associated with chemotherapy resistance in IGROVCDDP cells. Paclitaxel resistance in IGROVCDDP is mediated by gene and protein overexpression of P-glycoprotein and the protein is functionally active. Cisplatin resistance was not reversed by elacridar, confirming that cisplatin is not a P-glycoprotein substrate. Cisplatin resistance in IGROVCDDP is multifactorial and is mediated in part by the glutathione pathway and decreased accumulation of drug. Total cellular glutathione was not increased. However, the enzyme activity of GSR and GGT1 were up-regulated. The cellular localisation of copper transporter CTR1 changed from membrane associated in IGROV-1 to cytoplasmic in IGROVCDDP. This may mediate the previously reported accumulation defect. There was decreased expression of the sodium potassium pump (ATP1A), MRP1 and FBP which all have been previously associated with platinum accumulation defects in platinum-resistant cell lines. Cellular localisation of MRP1 was also altered in IGROVCDDP shifting basolaterally, compared to IGROV-1. BRCA1 was also up-regulated at the gene and protein level. The overexpression of P-glycoprotein in a resistant model developed with cisplatin is unusual. This demonstrates that P-glycoprotein can be up-regulated as a generalised stress response rather than as a specific response to a substrate. Mechanisms characterised in IGROVCDDP cells may be applicable to relapsed ovarian cancer patients treated with frontline platinum/taxane chemotherapy

Evaluating the named nurse understanding of recovery in forensic mental health

This article describes a service evaluation carried out on a personality disorder admission ward in a high-secure hospital to evaluate nurses understanding of recovery approaches in mental health. The study used semi-structured questionnaires to determine the participant’s understanding of recovery. The findings highlight that further development is required in staff training and education on recovery. Theories underpinning recovery principles also need to be disseminated to help nurses understand the relevance of current policy developments, and thus improve care

A small molecule activator of p300/CBP histone acetyltransferase promotes survival and neurite growth in a cellular model of Parkinson’s disease

Parkinson’s disease (PD) is a progressive neurodegenerative disease characterised by motor and non-motor symptoms, resulting from the degeneration of nigrostriatal dopaminergic neurons and peripheral autonomic neurons. Given the limited success of neurotrophic factors in clinical trials, there is a need to identify new small molecule drugs and drug targets to develop novel therapeutic strategies to protect all neurons that degenerate in PD. Epigenetic dysregulation has been implicated in neurodegenerative disorders, while targeting histone acetylation is a promising therapeutic avenue for PD. We and others have demonstrated that histone deacetylase inhibitors have neurotrophic effects in experimental models of PD. Activators of histone acetyltransferases (HAT) provide an alternative approach for the selective activation of gene expression, however little is known about the potential of HAT activators as drug therapies for PD. To explore this potential, the present study investigated the neurotrophic effects of CTPB (N-(4-chloro-3-trifluoromethyl-phenyl)-2-ethoxy-6-pentadecyl-benzamide), which is a potent small molecule activator of the histone acetyltransferase p300/CBP, in the SH-SY5Y neuronal cell line. We report that CTPB promoted the survival and neurite growth of the SH-SY5Y cells, and also protected these cells from cell death induced by the neurotoxin 6-hydroxydopamine. This study is the first to investigate the phenotypic effects of the HAT activator CTPB, and to demonstrate that p300/CBP HAT activation has neurotrophic effects in a cellular model of PD

A New Fossil Amiid from the Eocene of Senegal and the Persistence of Extinct Marine Amiids after the Cretaceous–Paleogene Boundary

We report a new fossil amiid from Eocene rocks of West Africa representing the first record of this clade from Senegal. The new specimen has a maxilla that is very similar in size to that of Amia calva. It is distinctly smaller than reported remains of another West African Eocene taxon, Maliamia gigas. We tentatively refer the Senegal specimen to Vidalamiini because it has the large postmaxillary process diagnostic of this clade; however, it also exhibits anatomical features not previously described in extinct amiids. We recovered the specimen in rocks of the Lam-Lam Formation in Central-Western Senegal that we interpret to have been a shallow marine depositional environment. The occurrence of an Eocene marine amiid contradicts existing hypotheses that marine amiids were generally absent after the Cretaceous– Paleogene boundary having been replaced by freshwater taxa. Research completed since the initial discovery of Maliamia gigas indicates that this Eocene taxon was also found in shallow marine rocks

Romidepsin induces caspase-dependent cell death in human neuroblastoma cells

Neuroblastoma is the most common extracranial pediatric solid tumor, arising from the embryonic sympathoadrenal lineage of the neural crest, and is responsible for 15% of childhood cancer deaths. Although survival rates are good for some patients, those children diagnosed with high-risk neuroblastoma have survival rates as low as 35%. Thus, neuroblastoma remains a significant clinical challenge and the development of novel therapeutic strategies is essential. Given that there is widespread epigenetic dysregulation in neuroblastoma, epigenetic pharmacotherapy holds promise as a therapeutic approach. In recent years, histone deacetylase (HDAC) inhibitors, which cause selective activation of gene expression, have been shown to be potent chemotherapeutics for the treatment of a wide range of cancers. Here we examined the ability of the FDA-approved drug Romidepsin, a selective HDAC1/2 inhibitor, to act as a cytotoxic agent in neuroblastoma cells. Treatment with Romidepsin at concentrations in the low nanomolar range induced neuroblastoma cell death through caspase-dependent apoptosis. Romidepsin significantly increased histone acetylation, and significantly enhanced the cytotoxic effects of the cytotoxic agent 6-hydroxydopamine, which has been shown to induce cell death in neuroblastoma cells through increasing reactive oxygen species. Romidepsin was also more potent in MYCN-amplified neuroblastoma cells, which is an important prognostic marker of poor survival. This study has thus demonstrated that the FDA-approved chemotherapeutic drug Romidepsin has a potent caspase-dependent cytotoxic effect on neuroblastoma cells, whose effects enhance cell death induced by other cytotoxins, and suggests that Romidepsin may be a promising chemotherapeutic candidate for the treatment of neuroblastoma